Chinese Academy of Sciences Aug 11 2025 Neuroblastoma is the most common solid tumor in infants and accounts for nearly 15% of all pediatric cancer-related deaths. Despite decades of progress in surgery, chemotherapy, and stem cell therapies, survival for high-risk patients remains under 60%. Current biomarkers—such as MYCN amplification or ALK mutations—offer limited reach, present only in subsets of patients or requiring complex testing. These limitations leave a critical gap in effectively